PR94284

DUBAI, UAE, Jan. 28, 2022 /PRNewswire=KYODO JBN/ --

Leading China-based biotech company Vazyme (688105.SH) participated in the 2022

edition of Medlab Middle East in the Dubai World Trade Centre (DWTC) from

January 24th to 27th, a leading laboratory and flagship exhibition and

conference that brings together global medical communities to display the best

laboratory innovation and technology. At Booth No. Z5.H20, the company

showcased its full product portfolios for COVID-19 testing solutions, as well

as advanced IVD products to online and in-person event visitors. Among the more

than 500 visitors, most of them were from Middle East region and the rest were

from India, Turkey, etc. The COVID-19 Antigen Rapid Self-Test Kit, which

produces test result in 10 minutes and achieves a 99.81% accuracy, was the most

popular product displayed.

"As the omicron variant starts to take hold, struggling hospitals and testing

centers are under increased strain, underscoring the imperative to boost up the

production of rapid and reliable COVID-19 test kits to track a new surging wave

of infections. We wish to help the medical communities in the Middle East and

Africa  region to address this issue by presenting our high-quality COVID-19

testing products and solutions at Medlab 2022 as a part of our effort to

strengthen local measures to combat the pandemic," said by Jenny Jiang,

International Business Manager of Vazyme.

At the event, Vazyme's entire lineup of Nucleic Acid Detection Solutions was on

full display, along with other products for COVID-19 detection that include

series of Antigen Detection Kits, COVID-19 Vaccine Antibody evaluation

solutions, and raw materials products of the detection solutions.  One of the

highlights of its exhibition, Vazyme Automatic Nucleic Acids Extraction System,

has obtained market approvals from the governments of UAE and Saudi Arabia, and

its 2019-nCoV Triplex RT-qPCR Detection Kit has also been recently authorized

to enter the UAE market.

Ten years into its existence, Vazyme has cemented its leadership in China's

biotech industry with a sufficient production capacity of IVD production line

equivalent to 1 million units per day. Vazyme's MENA-based team consists of IVD

product experts who offer all-around services and one-to-one installment

guidance to local consumers. Vazyme has ramped up its global expansion in 2021

by setting up its first wholly-owned overseas subsidiary in Indonesia, with its

offices and warehouses in the US, the EU, and Hong Kong SAR serving and

supporting worldwide customers.

"We will celebrate the 10th anniversary of our company since establishment this

year. As a forerunner advancing innovation in life science, Vazyme's mission is

to harness science and technology to improve health and life, addressing the

global unmet medical needs while holding ourselves to the highest standards of

ethics, accountability, and professionalism. Our R&D-centric approach allows us

to constantly innovate and bring new products and solutions to our customers.

We will continue to work with our partners across the globe, building on our

previous efforts to strengthen medical abilities in the fight against severe

illnesses," said by Jenny Jiang.

SOURCE  Vazyme

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=414035

   Caption: Vazyme at Medlab Middle East 2022